OnabotulinumtoxinA Disease Interactions
There are 3 disease interactions with onabotulinumtoxinA.
Botulinum toxin products (applies to onabotulinumtoxinA) dysphagia/respiratory/neuromuscular disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment, Myasthenia Gravis
Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA, letibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise. Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Patients treated with botulinum toxin may require immediate medical attention should they develop these complications. Caution is advised.
Botulinum toxin products (applies to onabotulinumtoxinA) infection
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, letibotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).
OnabotulinumtoxinA (applies to onabotulinumtoxinA) UTI
Major Potential Hazard, Moderate plausibility. Applicable conditions: Urinary Tract Infection, Urinary Retention
Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.
OnabotulinumtoxinA drug interactions
There are 119 drug interactions with onabotulinumtoxinA.
More about onabotulinumtoxinA
- onabotulinumtoxinA consumer information
- Check interactions
- Compare alternatives
- Reviews (489)
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: skeletal muscle relaxants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.